A citation-based method for searching scientific literature

Jessica L Mega, Sandra L Close, Stephen D Wiviott, Lei Shen, Richard D Hockett, John T Brandt, Joseph R Walker, Elliott M Antman, William Macias, Eugene Braunwald, Marc S Sabatine. N Engl J Med 2009
Times Cited: 1751







List of co-cited articles
627 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Stephen D Wiviott, Eugene Braunwald, Carolyn H McCabe, Gilles Montalescot, Witold Ruzyllo, Shmuel Gottlieb, Franz-Joseph Neumann, Diego Ardissino, Stefano De Servi, Sabina A Murphy,[...]. N Engl J Med 2007
36

Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.
S A Scott, K Sangkuhl, C M Stein, J-S Hulot, J L Mega, D M Roden, T E Klein, M S Sabatine, J A Johnson, A R Shuldiner. Clin Pharmacol Ther 2013
555
35

Genetic determinants of response to clopidogrel and cardiovascular events.
Tabassome Simon, Céline Verstuyft, Murielle Mary-Krause, Lina Quteineh, Elodie Drouet, Nicolas Méneveau, P Gabriel Steg, Jean Ferrières, Nicolas Danchin, Laurent Becquemont. N Engl J Med 2009
33

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Alan R Shuldiner, Jeffrey R O'Connell, Kevin P Bliden, Amish Gandhi, Kathleen Ryan, Richard B Horenstein, Coleen M Damcott, Ruth Pakyz, Udaya S Tantry, Quince Gibson,[...]. JAMA 2009
33

A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI.
Daniel M F Claassens, Gerrit J A Vos, Thomas O Bergmeijer, Renicus S Hermanides, Arnoud W J van 't Hof, Pim van der Harst, Emanuele Barbato, Carmine Morisco, Richard M Tjon Joe Gin, Folkert W Asselbergs,[...]. N Engl J Med 2019
182
33

Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Lars Wallentin, Richard C Becker, Andrzej Budaj, Christopher P Cannon, Håkan Emanuelsson, Claes Held, Jay Horrow, Steen Husted, Stefan James, Hugo Katus,[...]. N Engl J Med 2009
32

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Jessica L Mega, Tabassome Simon, Jean-Philippe Collet, Jeffrey L Anderson, Elliott M Antman, Kevin Bliden, Christopher P Cannon, Nicolas Danchin, Betti Giusti, Paul Gurbel,[...]. JAMA 2010
728
29

Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Larisa H Cavallari, Craig R Lee, Amber L Beitelshees, Rhonda M Cooper-DeHoff, Julio D Duarte, Deepak Voora, Stephen E Kimmel, Caitrin W McDonough, Yan Gong, Chintan V Dave,[...]. JACC Cardiovasc Interv 2018
142
22

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
Lars Wallentin, Stefan James, Robert F Storey, Martin Armstrong, Bryan J Barratt, Jay Horrow, Steen Husted, Hugo Katus, P Gabriel Steg, Svati H Shah,[...]. Lancet 2010
553
22

Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention.
Dirk Sibbing, Daniel Aradi, Dimitrios Alexopoulos, Jurrien Ten Berg, Deepak L Bhatt, Laurent Bonello, Jean-Philippe Collet, Thomas Cuisset, Francesco Franchi, Lisa Gross,[...]. JACC Cardiovasc Interv 2019
172
16

Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
Naveen L Pereira, Michael E Farkouh, Derek So, Ryan Lennon, Nancy Geller, Verghese Mathew, Malcolm Bell, Jang-Ho Bae, Myung Ho Jeong, Ivan Chavez,[...]. JAMA 2020
84
19



Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.
Miho Kazui, Yumi Nishiya, Tomoko Ishizuka, Katsunobu Hagihara, Nagy A Farid, Osamu Okazaki, Toshihiko Ikeda, Atsushi Kurihara. Drug Metab Dispos 2010
553
12

2018 ESC/EACTS Guidelines on myocardial revascularization.
Franz-Josef Neumann, Miguel Sousa-Uva, Anders Ahlsson, Fernando Alfonso, Adrian P Banning, Umberto Benedetto, Robert A Byrne, Jean-Philippe Collet, Volkmar Falk, Stuart J Head,[...]. Eur Heart J 2019
12

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
Jean-Philippe Collet, Jean-Sébastien Hulot, Anna Pena, Eric Villard, Jean-Baptiste Esteve, Johanne Silvain, Laurent Payot, Delphine Brugier, Guillaume Cayla, Farzin Beygui,[...]. Lancet 2009
697
12

2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Glenn N Levine, Eric R Bates, John A Bittl, Ralph G Brindis, Stephan D Fihn, Lee A Fleisher, Christopher B Granger, Richard A Lange, Michael J Mack, Laura Mauri,[...]. J Am Coll Cardiol 2016
760
12


Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.
Jean-Sébastien Hulot, Alessandra Bura, Eric Villard, Michel Azizi, Véronique Remones, Catherine Goyenvalle, Martine Aiach, Philippe Lechat, Pascale Gaussem. Blood 2006
681
11

Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Yilong Wang, Xingquan Zhao, Jinxi Lin, Hao Li, S Claiborne Johnston, Yi Lin, Yuesong Pan, Liping Liu, David Wang, Chunxue Wang,[...]. JAMA 2016
173
11

Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.
Guillaume Paré, Shamir R Mehta, Salim Yusuf, Sonia S Anand, Stuart J Connolly, Jack Hirsh, Katy Simonsen, Deepak L Bhatt, Keith A A Fox, John W Eikelboom. N Engl J Med 2010
393
10

Bedside monitoring to adjust antiplatelet therapy for coronary stenting.
Jean-Philippe Collet, Thomas Cuisset, Grégoire Rangé, Guillaume Cayla, Simon Elhadad, Christophe Pouillot, Patrick Henry, Pascal Motreff, Didier Carrié, Ziad Boueri,[...]. N Engl J Med 2012
636
10

2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).
Borja Ibanez, Stefan James, Stefan Agewall, Manuel J Antunes, Chiara Bucciarelli-Ducci, Héctor Bueno, Alida L P Caforio, Filippo Crea, John A Goudevenos, Sigrun Halvorsen,[...]. Eur Heart J 2018
10

Pharmacogenomic Approach to Selecting Antiplatelet Therapy in Patients With Acute Coronary Syndromes: The PHARMCLO Trial.
Francesca Maria Notarangelo, Giuseppe Maglietta, Paola Bevilacqua, Marco Cereda, Piera Angelica Merlini, Giovanni Quinto Villani, Paolo Moruzzi, Giampiero Patrizi, Guidantonio Malagoli Tagliazucchi, Antonio Crocamo,[...]. J Am Coll Cardiol 2018
86
11

Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium.
Roxana Mehran, Sunil V Rao, Deepak L Bhatt, C Michael Gibson, Adriano Caixeta, John Eikelboom, Sanjay Kaul, Stephen D Wiviott, Venu Menon, Eugenia Nikolsky,[...]. Circulation 2011
10

Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
Gregg W Stone, Bernhard Witzenbichler, Giora Weisz, Michael J Rinaldi, Franz-Josef Neumann, D Christopher Metzger, Timothy D Henry, David A Cox, Peter L Duffy, Ernest Mazzaferri,[...]. Lancet 2013
564
9

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
Jessica L Mega, Sandra L Close, Stephen D Wiviott, Lei Shen, Joseph R Walker, Tabassome Simon, Elliott M Antman, Eugene Braunwald, Marc S Sabatine. Lancet 2010
435
9

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.
Paul A Gurbel, Kevin P Bliden, Bonnie L Hiatt, Christopher M O'Connor. Circulation 2003
9

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.
J T Brandt, S L Close, S J Iturria, C D Payne, N A Farid, C S Ernest, D R Lachno, D Salazar, K J Winters. J Thromb Haemost 2007
558
9

Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
Matthew J Price, Peter B Berger, Paul S Teirstein, Jean-François Tanguay, Dominick J Angiolillo, Douglas Spriggs, Sanjeev Puri, Mark Robbins, Kirk N Garratt, Olivier F Bertrand,[...]. JAMA 2011
962
9

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
S Yusuf, F Zhao, S R Mehta, S Chrolavicius, G Tognoni, K K Fox. N Engl J Med 2001
9

Long-term use of ticagrelor in patients with prior myocardial infarction.
Marc P Bonaca, Deepak L Bhatt, Marc Cohen, Philippe Gabriel Steg, Robert F Storey, Eva C Jensen, Giulia Magnani, Sameer Bansilal, M Polly Fish, Kyungah Im,[...]. N Engl J Med 2015
9

Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.
Nicoline J Breet, Jochem W van Werkum, Heleen J Bouman, Johannes C Kelder, Henk J T Ruven, Egbert T Bal, Vera H Deneer, Ankie M Harmsze, Jan A S van der Heyden, Benno J W M Rensing,[...]. JAMA 2010
638
8

Clinical end points in coronary stent trials: a case for standardized definitions.
Donald E Cutlip, Stephan Windecker, Roxana Mehran, Ashley Boam, David J Cohen, Gerrit-Anne van Es, P Gabriel Steg, Marie-angèle Morel, Laura Mauri, Pascal Vranckx,[...]. Circulation 2007
8

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.
Jessica L Mega, Sandra L Close, Stephen D Wiviott, Lei Shen, Richard D Hockett, John T Brandt, Joseph R Walker, Elliott M Antman, William L Macias, Eugene Braunwald,[...]. Circulation 2009
484
8

Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis.
Yuesong Pan, Weiqi Chen, Yun Xu, Xingyang Yi, Yan Han, Qingwu Yang, Xin Li, Li'an Huang, S Claiborne Johnston, Xingquan Zhao,[...]. Circulation 2017
103
8

Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial.
Jason D Roberts, George A Wells, Michel R Le May, Marino Labinaz, Chris Glover, Michael Froeschl, Alexander Dick, Jean-Francois Marquis, Edward O'Brien, Sandro Goncalves,[...]. Lancet 2012
266
8

Paraoxonase-1 is a major determinant of clopidogrel efficacy.
Heleen J Bouman, Edgar Schömig, Jochem W van Werkum, Janna Velder, Christian M Hackeng, Christoph Hirschhäuser, Christopher Waldmann, Hans-Günther Schmalz, Jurriën M ten Berg, Dirk Taubert. Nat Med 2011
364
8

Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Dirk Sibbing, Dániel Aradi, Claudius Jacobshagen, Lisa Gross, Dietmar Trenk, Tobias Geisler, Martin Orban, Martin Hadamitzky, Béla Merkely, Róbert Gábor Kiss,[...]. Lancet 2017
242
8

Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention.
Dániel Aradi, Ajay Kirtane, Laurent Bonello, Paul A Gurbel, Udaya S Tantry, Kurt Huber, Matthias K Freynhofer, Jurrien ten Berg, Paul Janssen, Dominick J Angiolillo,[...]. Eur Heart J 2015
199
8

Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
Dirk Sibbing, Werner Koch, Daniela Gebhard, Tibor Schuster, Siegmund Braun, Julia Stegherr, Tanja Morath, Albert Schömig, Nicolas von Beckerath, Adnan Kastrati. Circulation 2010
416
8

Clopidogrel Pharmacogenetics.
Naveen L Pereira, Charanjit S Rihal, Derek Y F So, Yves Rosenberg, Ryan J Lennon, Verghese Mathew, Shaun G Goodman, Richard M Weinshilboum, Liewei Wang, Linnea M Baudhuin,[...]. Circ Cardiovasc Interv 2019
47
17


Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE Score.
Dominick J Angiolillo, Davide Capodanno, Nicolas Danchin, Tabassome Simon, Thomas O Bergmeijer, Jurrien M Ten Berg, Dirk Sibbing, Matthew J Price. JACC Cardiovasc Interv 2020
29
27

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
Steven R Steinhubl, Peter B Berger, J Tift Mann, Edward T A Fry, Augustin DeLago, Charles Wilmer, Eric J Topol. JAMA 2002
7

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
Marc S Sabatine, Christopher P Cannon, C Michael Gibson, Jose L López-Sendón, Gilles Montalescot, Pierre Theroux, Marc J Claeys, Frank Cools, Karen A Hill, Allan M Skene,[...]. N Engl J Med 2005
7


PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19.
Stuart A Scott, Katrin Sangkuhl, Alan R Shuldiner, Jean-Sébastien Hulot, Caroline F Thorn, Russ B Altman, Teri E Klein. Pharmacogenet Genomics 2012
105
7




Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.